Aardvark Therapeutics, Inc.
AARD
$13.96
$0.402.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.97M | 2.70M | 2.72M | 1.39M | 1.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.70M | 15.85M | 10.47M | 9.45M | 5.09M |
| Operating Income | -17.70M | -15.85M | -10.47M | -9.45M | -5.09M |
| Income Before Tax | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M |
| EBIT | -17.70M | -15.85M | -10.47M | -9.45M | -5.09M |
| EBITDA | -17.69M | -15.84M | -10.47M | -9.44M | -5.09M |
| EPS Basic | -0.75 | -0.66 | -0.71 | -2.16 | -1.05 |
| Normalized Basic EPS | -0.47 | -0.41 | -0.44 | -1.34 | -0.64 |
| EPS Diluted | -0.75 | -0.66 | -0.71 | -2.16 | -1.05 |
| Normalized Diluted EPS | -0.47 | -0.41 | -0.44 | -1.34 | -0.64 |
| Average Basic Shares Outstanding | 21.71M | 21.69M | 13.19M | 4.06M | 3.99M |
| Average Diluted Shares Outstanding | 21.71M | 21.69M | 13.19M | 4.06M | 3.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |